Press & Events
Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen will present the poster “PRGN-3005 UltraCAR-T™: Multigenic CAR-T Cells Generated Using Non-viral Gene Delivery and Rapid Manufacturing Process for the Treatment of Ovarian Cancer”. (Abstract 6593)
The conference call may be accessed by dialing 1-833-646-0488 (US/Canada toll-free) or 1-918-922-6615 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Participants may also access the live webcast through Precigen’s website at the link below.
The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1 412-317-6061 (International) and providing the number 4230814 to join the Precigen Conference Call.
Helen Sabzevari, PhD, President and CEO of Precigen, will present Precigen’s progress to date and a 2020 look ahead
Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen will present the poster “Preclinical Characterization of PRGN-3006 UltraCAR-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer.” (Abstract #2660)
Helen Sabzevari, PhD, President of Precigen, hosted a conference call to provide Precigen business and pipeline updates
Helen Sabzevari, PhD, President of Precigen, presented at JMP Securities Life Sciences Conference.
Helen Sabzevari, PhD, President of Precigen, presented at the 8th Annual SVB Leerink Global Healthcare Conference.